BCW Talks With General Biologic s Chervenak About the Upside and Challenges of the Chinese Biotech Market | GenomeWeb

With so many Western firms either expanding operations in China or looking to invest in that country's emerging biotech market, we sought the insights of someone with an insider's view of that market. This week, BioCommerce Week interviewed Matthew Chervenak, CEO of General Biologic, a Shanghai-based consultancy with 10 employees, about the opportunities and challenges companies face when they enter the Chinese market. Chervenak started the business about three years ago after working as both a scientist and as a strategy consultant in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.